Intravitreal injection of methotrexate in persistent diabetic macular edema
- Conditions
- Resistant macular edema in diabetic patients.Distrubtion of retinal layers due to edema
- Registration Number
- IRCT201610098983N2
- Lead Sponsor
- Guilan University of Medical Sciences,Vice chancellor for research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 42
1. Patient with central subfleid thickness (CST) More than 250 micrometers.
2. Best corrected visual acuity 20/ 200 and more.
3.lack of one line improvement, at least, in best corrected visual acuity or at least 10% reduction in central subfield thickness after intravitreal injection of three consecutive Bevacizumab and one injection co-administration bevacizumab -triamcinolone every 4-6week intervalor 3 consecutive Bevacizumab every 4 -6 weeks plus macular photouagulation.
4. Lack of traction on the macula, which is identified on clinical examination and OCT
5. Patient who agree entering the study (consent form)
Exclusion criteria :
1. Any previous intraocular surgery that was done in more than 1year ago
2. Any laser photocuagulation treatment in the past 4 months .
3. Need to any intraocular surgery, intraocular injection or laser photocoagulation in the follow-up period .
4. Any traction on the macula which is identified on clinical examination and OCT.
5. No control of blood pressure, blood sugar and blood lipid during study
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in macular thickness. Timepoint: 1, 3 and 6 months after injection. Method of measurement: OCT.
- Secondary Outcome Measures
Name Time Method Change in visual acuity. Timepoint: 1, 3 and 6 months after injection. Method of measurement: Snellen chart.